Pt Kalbe Farma Stock Current Asset
| PTKFF Stock | USD 0.1 0.00 0.00% |
PT Kalbe Farma fundamentals help investors to digest information that contributes to PT Kalbe's financial success or failures. It also enables traders to predict the movement of PTKFF Pink Sheet. The fundamental analysis module provides a way to measure PT Kalbe's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PT Kalbe pink sheet.
PTKFF |
PT Kalbe Farma Company Current Asset Analysis
PT Kalbe's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current PT Kalbe Current Asset | 9.22 T |
Most of PT Kalbe's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PT Kalbe Farma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, PT Kalbe Farma has a Current Asset of 9.22 T. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current asset for all United States stocks is significantly lower than that of the firm.
PTKFF Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PT Kalbe's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PT Kalbe could also be used in its relative valuation, which is a method of valuing PT Kalbe by comparing valuation metrics of similar companies.PT Kalbe is currently under evaluation in current asset category among its peers.
PTKFF Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Current Valuation | 6.11 B | |||
| Shares Outstanding | 46.26 B | |||
| Shares Owned By Insiders | 58.08 % | |||
| Shares Owned By Institutions | 15.23 % | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 3.56 X | |||
| Revenue | 26.26 T | |||
| Gross Profit | 11.11 T | |||
| EBITDA | 4.54 T | |||
| Net Income | 3.18 T | |||
| Cash And Equivalents | 189.29 M | |||
| Total Debt | 490.28 B | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 4.08 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | 2.83 T | |||
| Number Of Employees | 12.64 K | |||
| Beta | 0.32 | |||
| Market Capitalization | 7.34 B | |||
| Total Asset | 25.67 T | |||
| Retained Earnings | 10.82 T | |||
| Working Capital | 6.76 T | |||
| Current Asset | 9.22 T | |||
| Current Liabilities | 2.46 T | |||
| Z Score | 1.0 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 25.67 T |
About PT Kalbe Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PT Kalbe Farma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PT Kalbe using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PT Kalbe Farma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in PTKFF Pink Sheet
PT Kalbe financial ratios help investors to determine whether PTKFF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PTKFF with respect to the benefits of owning PT Kalbe security.